{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-120770","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.250063+00:00","generated_at":"2026-05-15T09:11:50.623809+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Karyopharm SENTRY trial meets spleen endpoint, misses symptom; DLBCL withdrawal agreed","bullets":["SENTRY trial: 50% SVR35 at wk24 vs 28% for ruxolitinib alone (p<0.0001); Abs-TSS comparable, not significant.","Promising OS signal: HR 0.43 (95% CI 0.19–1.00, nominal p=0.0222); continued follow-up planned.","FDA requested withdrawal of accelerated approval for XPOVIO in DLBCL; company agreed, ceases development.","Private placement with RA Capital: ~$30M gross (1.03M shares at $6.785, pre-funded warrants); warrants at $10.","ATM sales in March 2026 raised ~$9.6M net; capital raise trigger satisfied for credit agreement amendments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-120770","json":"https://secwatch.observer/filing/0001193125-26-120770.json","markdown":"https://secwatch.observer/filing/0001193125-26-120770.md","text":"https://secwatch.observer/filing/0001193125-26-120770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/0001193125-26-120770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/d125009d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:11:50.623809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45f86a62c10f15caf9c1509a909158b53e456f3d","claim":"Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with RA Capital Management valued at gross proceeds of approximately $30 million (effective 2026-03-24).","evidence_excerpt":"On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant, and (ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”) to the Investor in a private placement (collectively, the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/0001193125-26-120770-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"RA Capital Management"},{"label":"Value","value":"gross proceeds of approximately $30 million"},{"label":"Effective","value":"2026-03-24"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}